Company Overview and News
Have you been paying attention to shares of Statoil ASA (EQNR - Free Report) ? Shares have been on the move with the stock up 7% over the past month. EQNR hit a new 52-week high of $27.45 in the previous session. Statoil has gained 27.9% since the start of the year compared to the 12.1% move for the Oils-Energy sector and the 11.5% year-to-date return for its peer group.
*) exklusive kostnader för justering tilläggsköpeskilling ProntoTV AS på 705 TSEK, förvärvskostnader Qyn B.V. på 35 TSEK, förvävskostnader Seasam Oy 16 TSEK samt avstämning förvärvskostnader LiveQube AS på - 228 TSEK. Föregående år var det exklusive kostnader avseende listningsprocessen till Nasdaqs huvudmarknad på 1 798 TSEK.
At least that’s what traders were saying this week in Amsterdam at the Flame conference, the region’s biggest annual gas gathering. Rising prices for energy commodities led by oil and the need to refill depleted storage sites after the coldest winter since 2012 will see European gas consolidate its rare rally during the summer, when lower heating demand usually damps prices.
Investors focused on the Oils-Energy space have likely heard of Statoil ASA (STO - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.
Equinor ASA (OSE: EQNR, NYSE: STO), det nye foretaksnavnet til Statoil ASA, ble godkjent av selskapets generalforsamling i går, 15. mai 2018, og det nye navnet er nå registrert i Foretaksregisteret. Selskapets aksjer vil fra og med 16. mai 2018 handles på Oslo Børs med ticker EQNR.
Equinor ASA (OSE: EQNR, NYSE: STO), the new name of Statoil ASA, was approved by the annual general meeting yesterday, 15 May 2018, and the new name has now been registered in the Norwegian register of business enterprises (Foretaksregisteret). The company's shares will from 16 May 2018 (inclusive) be quoted on Oslo Børs with the new name and the new ticker EQNR.
På vegne av Statoil (OSE:STL, NYSE:STO) har DNB 15. mai 2018 kjøpt 424.908 aksjer til bruk i Statoils aksjespareprogram.
On behalf of Statoil (OSE: STL, NYSE:STO), DNB has on 15 May 2018 purchased 424,908 shares for use in the group's Share saving plan.
STAVANGER -- On May 15, 2018, the annual general meeting (AGM) in Statoil ASA will vote on the proposal to change the company’s name, from Statoil ASA to Equinor ASA.
Statoil ASA says it expects to implement its name change to Equinor ASA from, and including, May 16.
On 15 May 2018, the annual general meeting (AGM) in Statoil ASA (OSE: STL, NYSE:STO) will vote on the proposal to change the company's name, from Statoil ASA to Equinor ASA.
Den 15. mai 2018 skal generalforsamlingen i Statoil (OSE: STL, NYSE: STO) stemme over styrets forslag om å endre navn på selskapet, fra Statoil ASA til Equinor ASA.
Gemetchu Hika, company secretary in Statoil ASA (OSE:STL, NYSE:STO), has on 11 May 2018 sold 800 shares in Statoil ASA at a price of NOK 215,70 per share and will after the sale hold 954 shares in Statoil ASA.
Følgende primærinnsider i Statoil ASA (OSE:STL, NYSE:STO) har solgt aksjer i Statoil ASA: Gemetchu Hika, styresekretær i Statoil ASA, har den 11. mai 2018 solgt 800 aksjer i Statoil ASA til en pris per aksje på 215,70 kroner og vil etter salget eie 954 aksjer i Statoil ASA. Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12
Ørjan Kvelvane, direktør i Statoil ASA, har den 9. mai 2018 solgt 5.000 aksjer i Statoil ASA til en pris per aksje på 213,20 kroner og vil etter salget eie 1.449 aksjer i Statoil ASA.
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...
as of ET